Contra-indicated in patients with Crohn's disease.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Siliq (Valeant)
- INDICATIONS: Moderate-to-severe plaque psoriasis
- CLASS: Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Monoclonal antibody
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 02/15/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP450 substrates, Live vaccines - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
SUICIDAL IDEATION AND BEHAVIOR
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of brodalumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/05/2024
